Li X X, Li Y, Zhao X, Peng G X, Li J P, Ye L, Yang W R, Zhou K, Fan H H, Yang Y, Xiong Y Z, Li Y, Song L, Jing L P, Zhang L, Zhang F K
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Zhonghua Xue Ye Xue Za Zhi. 2022 Feb 14;43(2):115-119. doi: 10.3760/cma.j.issn.0253-2727.2022.02.005.
To reveal the compensatory features of bone marrow (BM) erythropoiesis in hereditary spherocytosis (HS) and to explore the effect of diferent hemoglobin levels on this compensation. Clinical and laboratory data of patients with HS were collected, and the peripheral blood absolute reticulocytes counts value was taken as the surrogate parameter to evaluate the ability of erythropoiesis compensation. BM erythropoiesis compensation in HS with diferent degrees of anemia were evaluated. ①Three hundred and two patients were enrolled, including 115 with compensated hemolytic disease, 74 with mild anemia, 90 with moderate anemia, and 23 with severe anemia. ②Hemoglobin (HGB) was negatively correlated with serum erythropoietin in the decompensated hemolytic anemia group (EPO; =-0.585, <0.001) . ③The median absolute reticulocyte count (ARC) of HS patients was 0.34 (0.27, 0.44) ×10(12)/L, up to 4.25 times that of normal people. The maximum ARC was 0.81×10(12)/L, about 10 times that of normal people. The median ARC of patients with compensated hemolytic disease was 0.29 (0.22, 0.38) ×10(12)/L, up to 3.63 times that of normal people. The median ARC of patients with hemolytic anemia was 0.38 (0.30, 0.46) ×10(12)/L, which was significantly higher than the patients with compensated hemolytic disease, up to 4.75 times that of normal people (=4.999, =0.003) . ④ ARC was negatively correlated with HGB in the compensated hemolytic disease group (=-0.177, =0.002) and positively correlated with HGB in the decompensated hemolytic anemia group (=0.191, =0.009) . There was no significant difference in the ARC among patients with mild, moderate, and severe anemia ((2)=4.588, =0.101) . ⑤The median immature reticulocyte production index of the mild, moderate, and severe anemia groups was 13.1% (9.1%, 18.4%) , 17.0% (13.4%, 20.8%) , and 17.8% (14.6%, 21.8%) , respectively; the mild anemia group had lower index values than the moderate and severe anemia groups ((adj) values were both<0.05) , but there was no significant difference between the latter groups ((adj)=1.000) . The median immature reticulocyte count of patients in the mild, moderate, and severe groups was 5.09 (2.60, 7.74) ×10(10)/L, 6.24 (4.34, 8.83) ×10(10)/L, and 7.00 (3.07, 8.22) ×10(10)/L, respectively; there was no significant difference among the groups ((2)=3.081, =0.214) . HGB can be maintained at a normal level through bone marrow erythropoiesis, while red blood cells are reduced in HS. However, once anemia develops, the bone marrow exerts its maximum erythropoiesis capacity and does not increase, regardless of anemia aggravation or serum EPO increase.
揭示遗传性球形红细胞增多症(HS)中骨髓红细胞生成的代偿特征,并探讨不同血红蛋白水平对这种代偿的影响。收集HS患者的临床和实验室数据,将外周血绝对网织红细胞计数作为评估红细胞生成代偿能力的替代参数。评估不同程度贫血的HS患者的骨髓红细胞生成代偿情况。①纳入302例患者,包括115例代偿性溶血性疾病患者、74例轻度贫血患者、90例中度贫血患者和23例重度贫血患者。②在失代偿性溶血性贫血组中,血红蛋白(HGB)与血清促红细胞生成素(EPO)呈负相关(r = -0.585,P < 0.001)。③HS患者的绝对网织红细胞计数中位数(ARC)为0.34(0.27,0.44)×10¹²/L,是正常人的4.25倍。最大ARC为0.81×10¹²/L,约为正常人的10倍。代偿性溶血性疾病患者的ARC中位数为0.29(0.22,0.38)×10¹²/L,是正常人的3.63倍。溶血性贫血患者的ARC中位数为0.38(0.30,0.46)×10¹²/L,显著高于代偿性溶血性疾病患者,是正常人的4.75倍(Z = 4.999,P = 0.003)。④在代偿性溶血性疾病组中,ARC与HGB呈负相关(r = -0.177,P = 0.002),在失代偿性溶血性贫血组中,ARC与HGB呈正相关(r = 0.191,P = 0.009)。轻度、中度和重度贫血患者之间的ARC无显著差异(χ² = 4.588,P = 0.101)。⑤轻度、中度和重度贫血组的未成熟网织红细胞生成指数中位数分别为13.1%(9.1%,18.4%)、17.0%(13.4%,20.8%)和17.8%(14.6%,21.8%);轻度贫血组的指数值低于中度和重度贫血组(校正P值均<0.05),但后两组之间无显著差异(校正P = 1.000)。轻度、中度和重度组患者的未成熟网织红细胞计数中位数分别为5.09(2.60,7.74)×10¹⁰/L、6.24(4.34,8.83)×10¹⁰/L和7.00(3.07,8.22)×10¹⁰/L;各组之间无显著差异(χ² = 3.08l,P = 0.214)。在HS中,HGB可通过骨髓红细胞生成维持在正常水平,而红细胞减少。然而,一旦发生贫血,无论贫血加重或血清EPO升高,骨髓都会发挥其最大的红细胞生成能力且不再增加。